EE03399B1 - Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess - Google Patents

Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess

Info

Publication number: EE03399B1
Authority: EE; Estonia
Prior art keywords: spiro; therapy; preparation; compounds used; azabicyclic compounds
Prior art date: 1994-08-24

Application number

EE9700039A

Other languages

English (en)

Estonian (et)

Other versions

EE9700039A (et

Inventor

Charles Gordon John

Conrad Griffith Ronald

John Murray Robert

Balestra Michael

Original Assignee

Astra Aktiebolag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-24

Filing date

1995-08-22

Publication date

2001-04-16

1994-08-24 Priority claimed from GB9417084A external-priority patent/GB9417084D0/en

1995-03-08 Priority claimed from GBGB9504627.2A external-priority patent/GB9504627D0/en

1995-08-22 Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag

1997-08-15 Publication of EE9700039A publication Critical patent/EE9700039A/xx

2001-04-16 Publication of EE03399B1 publication Critical patent/EE03399B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

EE9700039A 1994-08-24 1995-08-22 Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess EE03399B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9417084A GB9417084D0 (en)	1994-08-24	1994-08-24	Compounds useful in therapy
GBGB9504627.2A GB9504627D0 (en)	1995-03-08	1995-03-08	Compounds for use in therapy
PCT/SE1995/000937 WO1996006098A1 (en)	1994-08-24	1995-08-22	Spiro-azabicyclic compounds useful in therapy

Publications (2)

Publication Number	Publication Date
EE9700039A EE9700039A (et)	1997-08-15
EE03399B1 true EE03399B1 (et)	2001-04-16

Family

ID=26305509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9700039A EE03399B1 (et)	1994-08-24	1995-08-22	Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess

Country Status (33)

Country	Link
US (2)	US5902814A (pt)
EP (1)	EP0777671B1 (pt)
JP (1)	JP3708962B2 (pt)
KR (1)	KR100366331B1 (pt)
CN (2)	CN1056846C (pt)
AR (1)	AR031828A2 (pt)
AT (1)	ATE192157T1 (pt)
AU (1)	AU690735B2 (pt)
BR (1)	BR9508751A (pt)
CA (1)	CA2196995C (pt)
CZ (1)	CZ289512B6 (pt)
DE (1)	DE69516524T2 (pt)
DK (1)	DK0777671T3 (pt)
EE (1)	EE03399B1 (pt)
EG (1)	EG24222A (pt)
ES (1)	ES2145922T3 (pt)
FI (1)	FI112868B (pt)
GR (1)	GR3033878T3 (pt)
HU (1)	HUT77352A (pt)
IL (1)	IL115039A (pt)
IS (1)	IS1852B (pt)
MX (1)	MX9701292A (pt)
NO (1)	NO307707B1 (pt)
NZ (1)	NZ292289A (pt)
PL (1)	PL183933B1 (pt)
PT (1)	PT777671E (pt)
RU (1)	RU2148058C1 (pt)
SA (1)	SA95160370B1 (pt)
SK (1)	SK282366B6 (pt)
TR (1)	TR199501053A2 (pt)
TW (1)	TW397837B (pt)
UA (1)	UA54375C2 (pt)
WO (1)	WO1996006098A1 (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5977144A (en) *	1992-08-31	1999-11-02	University Of Florida	Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
AR013184A1 (es) *	1997-07-18	2000-12-13	Astrazeneca Ab	Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en)	1998-05-04	2001-08-21	Astra Ab	Use
SE9900100D0 (sv) *	1999-01-15	1999-01-15	Astra Ab	New compounds
JP4564135B2 (ja) *	1999-07-26	2010-10-20	住友化学株式会社	高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶
WO2001066546A1 (en) *	2000-03-09	2001-09-13	Mitsubishi Pharma Corporation	Spiro compounds, process for preparing the same and use thereof as drugs
US8914114B2 (en)	2000-05-23	2014-12-16	The Feinstein Institute For Medical Research	Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
EP1317460A4 (en) *	2000-08-28	2005-04-20	Univ Colorado State Res Found	COMPOUNDS CONTAINING OXAZOLIDINONE FRAGMENT AND USES
US6569865B2 (en)	2001-06-01	2003-05-27	Astrazeneca Ab	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AU2002339810A1 (en) *	2001-10-16	2003-04-28	Astrazeneca Ab	Azabicyclic compounds for the treatment of fibromyalgia syndrome
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
CA2476896A1 (en) *	2002-02-26	2003-09-04	North Shore-Long Island Jewish Research Institute	Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
SE0202598D0 (sv) *	2002-09-02	2002-09-02	Astrazeneca Ab	Alpha-7 Nicotinic receptor agonists and statins in combination
US7238715B2 (en)	2002-12-06	2007-07-03	The Feinstein Institute For Medical Research	Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN102657651A (zh) *	2002-12-06	2012-09-12	范因斯坦医学研究院	用α 7受体结合胆碱能激动剂抑制炎症
EP1654264A1 (en) *	2003-07-08	2006-05-10	AstraZeneca AB	Spiro [1-azabicyclo [2.2.2]octane-3,5'-oxazolidin-2'-one] derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
EP1734941A2 (en) *	2004-03-25	2006-12-27	The Feinstein Institute for Medical Research	Neural tourniquet
US10912712B2 (en)	2004-03-25	2021-02-09	The Feinstein Institutes For Medical Research	Treatment of bleeding by non-invasive stimulation
CA2591430A1 (en) *	2004-12-15	2006-06-22	Astrazeneca Ab	Nicotinic acetylcholine receptor ligands
US11207518B2 (en)	2004-12-27	2021-12-28	The Feinstein Institutes For Medical Research	Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CA2593079C (en)	2004-12-27	2014-08-19	North Shore-Long Island Jewish Research Institute	Treating inflammatory disorders by electrical vagus nerve stimulation
WO2006071184A1 (en) *	2004-12-28	2006-07-06	Astrazeneca Ab	Aryl sulphonamide modulators
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) *	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
RU2326787C2 (ru) *	2005-11-09	2008-06-20	Сергей Федорович Бокарев	Способ управления крылом, помещенным в текучую среду, при его взаимодействии с этой средой и устройство для его осуществления
US8316104B2 (en)	2005-11-15	2012-11-20	California Institute Of Technology	Method and apparatus for collaborative system
WO2008028903A2 (en)	2006-09-04	2008-03-13	Neurosearch A/S	Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
WO2009029614A1 (en)	2007-08-27	2009-03-05	The Feinstein Institute For Medical Research	Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102008015999B4 (de)	2008-03-27	2011-04-21	Novar Gmbh	Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage
WO2009146030A1 (en) *	2008-03-31	2009-12-03	The Feinstein Institute For Medical Research	Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en)	2008-03-31	2017-05-30	The Feinstein Institute For Medical Research	Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US8309577B2 (en)	2008-04-23	2012-11-13	Bristol-Myers Squibb Company	Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) *	2008-04-23	2011-01-04	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
TWI488854B (zh)	2008-06-20	2015-06-21	Astrazeneca Ab	二苯并噻氮呯衍生物及其用途
US8412338B2 (en)	2008-11-18	2013-04-02	Setpoint Medical Corporation	Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
SI2355822T1 (sl)	2008-11-19	2013-02-28	Envivo Pharmaceuticals, Inc.	Zdravljenje kognitivnih motenj z (R)-7-kloro-N-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamidom in njegovimi farmacevtsko sprejemljivimi solmi
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9211410B2 (en)	2009-05-01	2015-12-15	Setpoint Medical Corporation	Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en)	2009-10-30	2015-03-31	Setpoint Medical Corporation	Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
CN102802620A (zh) *	2009-05-11	2012-11-28	英维沃医药有限公司	使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
EP2440284B1 (en)	2009-06-09	2018-09-12	Setpoint Medical Corporation	Nerve cuff with pocket for leadless stimulator
CN102686595A (zh)	2009-10-28	2012-09-19	百时美施贵宝公司	作为α-7 烟碱乙酰胆碱受体配体的氮杂二环化合物
US8278320B2 (en)	2009-10-28	2012-10-02	Bristol-Myers Squibb Company	Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US11051744B2 (en)	2009-11-17	2021-07-06	Setpoint Medical Corporation	Closed-loop vagus nerve stimulation
US9833621B2 (en)	2011-09-23	2017-12-05	Setpoint Medical Corporation	Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (en)	2009-12-23	2019-09-18	Setpoint Medical Corporation	Neural stimulation devices and systems for treatment of chronic inflammation
WO2011137313A1 (en)	2010-04-30	2011-11-03	Bristol-Myers Squibb Company	Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
PE20130218A1 (es)	2010-05-17	2013-03-20	Envivo Pharmaceuticals Inc	Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
CN103619405B (zh)	2011-05-09	2015-11-25	赛博恩特医疗器械公司	用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活
US12172017B2 (en)	2011-05-09	2024-12-24	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
GB201111704D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Novel compounds
GB201111705D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Compounds and their use
JO3115B1 (ar)	2011-08-22	2017-09-20	Takeda Pharmaceuticals Co	مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en)	2012-03-26	2017-02-21	Setpoint Medical Corporation	Devices and methods for modulation of bone erosion
EP2846796A4 (en)	2012-05-08	2015-10-21	Forum Pharmaceuticals Inc	METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
GB201209587D0 (en)	2012-05-30	2012-07-11	Takeda Pharmaceutical	Therapeutic compounds
WO2014122474A1 (en)	2013-02-07	2014-08-14	Takeda Pharmaceutical Company Limited	Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
EA029430B1 (ru)	2013-06-21	2018-03-30	Такеда Фармасьютикл Компани Лимитед	Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en)	2013-08-08	2013-09-25	Takeda Pharmaceutical	Therapeutic Compounds
GB201318222D0 (en)	2013-10-15	2013-11-27	Takeda Pharmaceutical	Novel compounds
GB201320905D0 (en)	2013-11-27	2014-01-08	Takeda Pharmaceutical	Therapeutic compounds
TW201613864A (en)	2014-02-20	2016-04-16	Takeda Pharmaceutical	Novel compounds
US11311725B2 (en)	2014-10-24	2022-04-26	Setpoint Medical Corporation	Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en)	2015-02-03	2022-08-09	Setpoint Medical Corporation	Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en)	2016-01-13	2020-03-24	Setpoint Medical Corporation	Systems and methods for establishing a nerve block
CN114904142A (zh)	2016-01-20	2022-08-16	赛博恩特医疗器械公司	迷走神经刺激的控制
WO2017127758A1 (en)	2016-01-20	2017-07-27	Setpoint Medical Corporation	Implantable microstimulators and inductive charging systems
US11471681B2 (en)	2016-01-20	2022-10-18	Setpoint Medical Corporation	Batteryless implantable microstimulators
US10583304B2 (en)	2016-01-25	2020-03-10	Setpoint Medical Corporation	Implantable neurostimulator having power control and thermal regulation and methods of use
US11745039B2 (en)	2016-07-25	2023-09-05	Tonal Systems, Inc.	Assisted racking of digital resistance
US10661112B2 (en)	2016-07-25	2020-05-26	Tonal Systems, Inc.	Digital strength training
GB201616839D0 (en)	2016-10-04	2016-11-16	Takeda Pharmaceutical Company Limited	Therapeutic compounds
GB201619514D0 (en)	2016-11-18	2017-01-04	Takeda Pharmaceuticals Co	Novel compounds
US11173307B2 (en)	2017-08-14	2021-11-16	Setpoint Medical Corporation	Vagus nerve stimulation pre-screening test
US10589163B2 (en)	2017-10-02	2020-03-17	Tonal Systems, Inc.	Exercise machine safety enhancements
US10486015B2 (en)	2017-10-02	2019-11-26	Tonal Systems, Inc.	Exercise machine enhancements
US10335626B2 (en)	2017-10-02	2019-07-02	Tonal Systems, Inc.	Exercise machine with pancake motor
US10617903B2 (en)	2017-10-02	2020-04-14	Tonal Systems, Inc.	Exercise machine differential
US11660443B2 (en)	2018-04-20	2023-05-30	The Feinstein Institutes For Medical Research	Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en)	2018-09-25	2022-03-01	The Feinstein Institutes For Medical Research	Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en)	2019-04-12	2025-11-20	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
EP4090424A4 (en)	2020-01-13	2024-02-21	The Feinstein Institutes for Medical Research	TREATMENT OF BLEEDING AND BLEEDING DISORDERS BY HIGH-INTENSITY FOCUSED ULTRASONIC STIMULATION OF THE SPLEEN
JP2021138648A (ja)	2020-03-04	2021-09-16	武田薬品工業株式会社	経口固形製剤
IL304787B2 (en)	2020-05-21	2025-12-01	Feinstein Institutes For Medical Research	Systems and methods for vagus nerve stimulation
US11285355B1 (en)	2020-06-08	2022-03-29	Tonal Systems, Inc.	Exercise machine enhancements
US11878204B2 (en)	2021-04-27	2024-01-23	Tonal Systems, Inc.	First repetition detection
US11998804B2 (en)	2021-04-27	2024-06-04	Tonal Systems, Inc.	Repetition phase detection
US12444497B2 (en)	2021-05-17	2025-10-14	Setpoint Medical Corporation	Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH601304A5 (pt) *	1974-02-12	1978-07-14	Buskine Sa
US4028351A (en) *	1971-09-07	1977-06-07	Buskine S.A.	Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained
SU495310A1 (ru) *	1974-03-05	1975-12-15	Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе	Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени
GB8808433D0 (en) *	1988-04-11	1988-05-11	Merck Sharp & Dohme	Therapeutic agents
GB8816299D0 (en) *	1988-07-08	1988-08-10	Merck Sharp & Dohme	Therapeutic agents
IL97726A (en) *	1990-04-10	1994-12-29	Israel Inst Biolog Res	Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5534520A (en) *	1990-04-10	1996-07-09	Fisher; Abraham	Spiro compounds containing five-membered rings
US5073560A (en) *	1990-07-20	1991-12-17	Fisons Corporation	Spiro-isoxazolidine derivatives as cholinergic agents
US5137895A (en) *	1991-04-29	1992-08-11	A. H. Robins Company, Incorporated	3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols

1995
- 1995-08-22 SK SK216-97A patent/SK282366B6/sk not_active IP Right Cessation
- 1995-08-22 BR BR9508751A patent/BR9508751A/pt not_active IP Right Cessation
- 1995-08-22 AU AU34018/95A patent/AU690735B2/en not_active Ceased
- 1995-08-22 WO PCT/SE1995/000937 patent/WO1996006098A1/en not_active Ceased
- 1995-08-22 KR KR1019970701159A patent/KR100366331B1/ko not_active Expired - Fee Related
- 1995-08-22 HU HU9701965A patent/HUT77352A/hu unknown
- 1995-08-22 AT AT95930755T patent/ATE192157T1/de not_active IP Right Cessation
- 1995-08-22 CZ CZ1997392A patent/CZ289512B6/cs not_active IP Right Cessation
- 1995-08-22 EP EP95930755A patent/EP0777671B1/en not_active Expired - Lifetime
- 1995-08-22 UA UA97031329A patent/UA54375C2/uk unknown
- 1995-08-22 ES ES95930755T patent/ES2145922T3/es not_active Expired - Lifetime
- 1995-08-22 CN CN95195518A patent/CN1056846C/zh not_active Expired - Fee Related
- 1995-08-22 NZ NZ292289A patent/NZ292289A/en not_active IP Right Cessation
- 1995-08-22 DK DK95930755T patent/DK0777671T3/da active
- 1995-08-22 CA CA002196995A patent/CA2196995C/en not_active Expired - Fee Related
- 1995-08-22 JP JP50799596A patent/JP3708962B2/ja not_active Expired - Fee Related
- 1995-08-22 RU RU97104165A patent/RU2148058C1/ru not_active IP Right Cessation
- 1995-08-22 PL PL95318760A patent/PL183933B1/pl not_active IP Right Cessation
- 1995-08-22 DE DE69516524T patent/DE69516524T2/de not_active Expired - Fee Related
- 1995-08-22 MX MX9701292A patent/MX9701292A/es unknown
- 1995-08-22 EE EE9700039A patent/EE03399B1/xx not_active IP Right Cessation
- 1995-08-22 US US08/525,575 patent/US5902814A/en not_active Expired - Fee Related
- 1995-08-22 PT PT95930755T patent/PT777671E/pt unknown
- 1995-08-23 EG EG70395A patent/EG24222A/xx active
- 1995-08-23 IL IL11503995A patent/IL115039A/xx not_active IP Right Cessation
- 1995-08-24 TR TR95/01053A patent/TR199501053A2/xx unknown
- 1995-08-24 TW TW084108836A patent/TW397837B/zh not_active IP Right Cessation
- 1995-11-08 SA SA95160370A patent/SA95160370B1/ar unknown
1997
- 1997-02-03 IS IS4424A patent/IS1852B/is unknown
- 1997-02-21 NO NO970800A patent/NO307707B1/no not_active IP Right Cessation
- 1997-02-24 FI FI970762A patent/FI112868B/fi active
1998
- 1998-11-09 US US09/188,099 patent/US6051581A/en not_active Expired - Fee Related
1999
- 1999-11-08 CN CN99123574A patent/CN1099419C/zh not_active Expired - Fee Related
2000
- 2000-04-10 AR ARP000101632A patent/AR031828A2/es unknown
- 2000-07-04 GR GR20000401563T patent/GR3033878T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1010370A1 (en)	1999-06-17
PL318760A1 (en)	1997-07-07
NZ292289A (en)	1998-05-27
EP0777671B1 (en)	2000-04-26
JP3708962B2 (ja)	2005-10-19
CN1056846C (zh)	2000-09-27
FI970762L (fi)	1997-02-24
TW397837B (en)	2000-07-11
AU3401895A (en)	1996-03-14
PT777671E (pt)	2000-08-31
US5902814A (en)	1999-05-11
GR3033878T3 (en)	2000-11-30
NO970800D0 (no)	1997-02-21
DE69516524T2 (de)	2001-01-18
JPH10504561A (ja)	1998-05-06
FI970762A0 (fi)	1997-02-24
RU2148058C1 (ru)	2000-04-27
CZ289512B6 (cs)	2002-02-13
NO307707B1 (no)	2000-05-15
ES2145922T3 (es)	2000-07-16
DK0777671T3 (da)	2000-07-24
US6051581A (en)	2000-04-18
DE69516524D1 (de)	2000-05-31
BR9508751A (pt)	1997-08-12
CN1099419C (zh)	2003-01-22
CN1159808A (zh)	1997-09-17
SK282366B6 (sk)	2002-01-07
UA54375C2 (uk)	2003-03-17
CA2196995A1 (en)	1996-02-29
IL115039A0 (en)	1995-12-08
MX9701292A (es)	1997-05-31
WO1996006098A1 (en)	1996-02-29
IL115039A (en)	2001-08-26
NO970800L (no)	1997-02-21
PL183933B1 (pl)	2002-08-30
AU690735B2 (en)	1998-04-30
CA2196995C (en)	2008-05-13
EE9700039A (et)	1997-08-15
ATE192157T1 (de)	2000-05-15
SK21697A3 (en)	1997-09-10
SA95160370B1 (ar)	2006-06-04
HUT77352A (hu)	1998-03-30
TR199501053A2 (tr)	1996-06-21
EP0777671A1 (en)	1997-06-11
IS4424A (is)	1997-02-03
EG24222A (en)	2008-11-10
CZ39297A3 (en)	1997-12-17
IS1852B (is)	2003-02-21
KR100366331B1 (ko)	2003-04-10
FI112868B (fi)	2004-01-30
CN1284505A (zh)	2001-02-21
AR031828A2 (es)	2003-10-08

Publication	Publication Date	Title
EE03399B1 (et)	2001-04-16	Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess
FI962954A7 (fi)	1996-07-24	Substituoidut 3-arylideeni-7-atsaoksindoliyhdisteet ja menetelmä niiden valmistamiseksi
EE9700145A (et)	1998-02-16	Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
FI960751A7 (fi)	1996-02-19	Substituoidut atsaindolylideeniyhdisteet ja menetelmä niiden valmistamiseksi
EE9700153A (et)	1998-02-16	Heterotsükliga kondenseerunud püridiinid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
FI951305L (fi)	1995-03-20	Lääketieteellinen materiaali ja menetelmä sen valmistamiseksi
FI941137L (fi)	1994-09-12	2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI970918L (fi)	1997-05-02	Yhdisteet ja menetelmät syövän hoitamiseksi
EE9700060A (et)	1997-10-15	2-arüül-asendatud püridiinid,nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
FI964102L (fi)	1996-12-11	Menetelmä fenolin ja fenolijohdannaisten valmistamiseksi
FI951468A7 (fi)	1995-10-01	Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
FI953919A7 (fi)	1995-08-21	Pyrrolydeenimetyylijohdannaiset ja menetelmä niiden valmistamiseksi
FI944600A0 (fi)	1994-10-03	Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
FI971268A7 (fi)	1997-03-26	Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
FI955426L (fi)	1995-11-10	Pintakäsittelytuotteet ja menetelmät niiden valmistamiseksi
FI944713L (fi)	1994-12-02	4-difenyylimetyylipiperidiinijohdannaisia ja menetelmä niiden valmistamiseksi
FI951060A7 (fi)	1995-09-09	Formulaatioita ja hoitomenetelmiä
EE9700288A (et)	1998-04-15	Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
FI972235L (fi)	1997-05-27	Menetelmä triaryylietyleenijohdannaisten käyttämiseksi osteoporoosin hoidossa ja ehkäisyssä
FI931414A7 (fi)	1993-10-02	Imidatsolijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
EE03878B1 (et)	2002-10-15	5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete ühendite valmistamiseks
FI964901L (fi)	1997-02-07	Menetelmä alfa-metoksi-iminokarboksyylihappometyyliamidien valmistamiseksi ja menetelmässä käytettyjä välituotteita
FI965008L (fi)	1996-12-13	Koostumukset ja menetelmät kasvainten hoitamiseksi
EE9800333A (et)	1999-04-15	Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
FI905173A7 (fi)	1991-04-24	Diatsabisykloamiiniyhdisteet ja menetelmä niiden valmistamiseksi

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2010-04-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20090822